Abstract:Background: When ovarian carcinoma is diagnosed in stage I, up to 90% of patients can be cured with surgery and currently available chemotherapy. At present, less than 25% of cases are diagnosed at this stage. To increase the fraction of ovarian cancers detected at an early stage, screening strategies have been devised that utilize a rising serum CA125 level to trigger the performance of transvaginal sonography. One limitation of CA125 as an initial step in such a screening strategy is that up to 20% of ovarian cancers lack expression of the antigen. Serum tumor markers that can be detected in ovarian cancers that lack CA125 expression might improve the sensitivity for early detection. Methods: From 296 ovarian cancers, 65 (22%) were found to have weak or absent CA125 expression on immunoperoxidase staining. Tissue expression of CA125 was compared to serum CA125 levels. Using immunoperoxidase staining of tissue arrays, we have assessed expression of 10 potential serum tumor markers in the 65 epithelial ovarian cancers with little or no CA125 expression and in ovarian cystadenomas, tumors of low malignant potential, normal ovaries, and 16 other normal tissues. Results: Low or absent expression of CA125 in surgical specimens of epithelial ovarian cancer was associated with low levels of serum CA125 in pre-operative serum specimens. In ovarian cancers that lacked CA125, all specimens (100%) expressed human kallikrein 10 (HK10), human kallikrein 6 (HK6), osteopontin (OPN), and claudin 3. A smaller fraction of CA125-deficient ovarian cancers expressed DF3 (95%), vascular endothelial growth factor (VEGF) (81%), MUC1 (62%), mesothelin (MES) (34%), HE4 (32%), and CA19-9 (29%). When reactivity with normal tissues was considered, however, MES and HE4 showed the greatest specificity. Differential expression was also found for HK10, OPN, DF3, and MUC1. Conclusions: At the level of tissue expression, each of 10 potential serum markers could be detected in 29-100% of ovarian cancers that had low or absent expression of CA125. Several markers exhibited more intense expression in cancers than in normal organs. Further investigation is needed to demonstrate complementary expression of markers in serum.

Tumor markers for early detection of ovarian cancer

Advances in tumor markers of ovarian cancer for early diagnosis

Tumor Markers and Their Diagnostic Significance in Ovarian Cancer

An overview of biomarkers for the ovarian cancer diagnosis

A Multiplex Methylation-Specific Pcr Assay For Detection Of Early-Stage Ovarian Cancer Using Cell-Free Serum Dna

Sensitivity and Specificity of Selected Biomarkers and Their Combinations in the Diagnosis of Ovarian Cancer (Review)

Platelet RNA Enables Accurate Detection of Ovarian Cancer: an Intercontinental, Biomarker Identification Study.

Proteomic markers for early detection of ovarian cancer

Early Diagnosis of Ovarian Carcinoma: Is a Solution in Sight?

Early Ovarian Cancer Detection in the Age of Fallopian Tube Precursors

A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA.

Potential markers that complement expression of CA125 in epithelial ovarian cancer

Early detection of ovarian cancer using cell-free DNA fragmentomes and protein biomarkers

The role of urine and serum biomarkers in the early detection of ovarian epithelial tumours

Identifying Potential Markers for Monitoring Progression to Ovarian Cancer Using Plasma Label-free Proteomics

Metabolomic biomarkers for benign conditions and malignant ovarian cancer: Advancing early diagnosis

Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer.

Combined use of biomarkers for detection of ovarian cancer in high-risk women

Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets

Automated early ovarian cancer detection system based on bioinformatics

Research Progress of MicroRNA in Early Detection of Ovarian Cancer.